Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.43 |
| ▸ | CCNC | P24863 | 2/20 | 0.40 |
| ▸ | CDK8 | P49336 | 2/20 | 0.40 |
| ▸ | ABL1 | P00519 | 4/20 | 0.39 |
| ▸ | BCR | P11274 | 4/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TACR3 | P29371 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3660847 | 0.90 | HRH3 (0.44) | HRH3CCNCCDK8ABL1BCR | |
| SCHEMBL3723325 | 0.90 | HRH3 (0.44) | HRH3CCNCCDK8ABL1BCR | |
| SCHEMBL3656411 | 0.89 | ABL1 (0.44) | HRH3CCNCCDK8ABL1BCR | |
| SCHEMBL3659562 | 0.84 | HRH3 (0.45) | HRH3ABL1BCRGRM5SLC6A7 | |
| SCHEMBL2241835 | 0.78 | POLB (0.45) | CCNCCDK8ABL1BCRGRM5 | |
| SCHEMBL2237541 | 0.78 | HPGD (0.45) | CCNCCDK8ABL1BCRGRM5 | |
| SCHEMBL3659805 | 0.78 | ABL1 (0.46) | HRH3ABL1BCRSLC6A7CHRNA7 | |
| SCHEMBL15338652 | 0.77 | MGLL (0.40) | HRH3CCNCCDK8ABL1BCR | |
| SCHEMBL13743227 | 0.77 | HRH3 (0.53) | HRH3CCNCCDK8SLC6A7CHRNA7 | |
| SCHEMBL3663032 | 0.76 | ABL1 (0.48) | HRH3ABL1BCRSLC6A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231642-B1 | PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-10-23 | — | — | EP | claimed |
| US-8431578-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-04-30 | — | — | US | claimed |
| CN-101910153-A | Pyrimidines as kinase inhibitors | NOVARTIS AG | 2010-12-08 | — | — | CN | claimed |
| US-20100298337-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-25 | — | — | US | claimed |
| EP-2231642-A1 | PYRIMIDINES AS KINASE INHIBITORS | Novartis AG (CH) | 2010-09-29 | — | — | EP | claimed |
| WO-2009087224-A1 | PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | claimed |
| EP-2231642-B1 | PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| EP-2231642-B1 | PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-8431578-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-04-30 | — | — | US | disclosed |
| US-8431578-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-04-30 | — | — | US | disclosed |
| US-8431578-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-04-30 | — | — | US | disclosed |
| CN-101910153-A | Pyrimidines as kinase inhibitors | NOVARTIS AG | 2010-12-08 | — | — | CN | disclosed |
| US-20100298337-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-25 | — | — | US | disclosed |
| US-20100298337-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-25 | — | — | US | disclosed |
| US-20100298337-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-25 | — | — | US | disclosed |
| EP-2231642-A1 | PYRIMIDINES AS KINASE INHIBITORS | Novartis AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009087224-A1 | PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298337-A1 | Organic Compounds | CYP11B2, TNNT2, CPT1B | HRH3 1989/4885CCNC 984/4885CDK8 2339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.